News – Abzena

Filter by year

Filter by topic

Full year results: integration and growth seen across the Group, with 41% underlying increase in revenues

Cambridge, UK, 13 June 2017 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, has published its full year results for the year to 31 March 2017. Corporate highlights Integration of Abzena’s service offering for biopharmaceutical development and manufacturing […] Read more

Bioverativ to acquire True North Therapeutics and the Abzena Inside portfolio product, TNT009

Cambridge, UK, 24 May 2017 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, notes the announcement from Bioverativ Inc. (NASDAQ: BIVV), that it has entered into a definitive agreement to acquire True North Therapeutics for an upfront payment of […] Read more

Notice of full year results

Cambridge, UK, 16 May 2017 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, will publish its full year results for the year to 31 March 2017 on Tuesday, 13 June 2017. A presentation for analysts will be held […] Read more

Abzena to pursue $12 million investment program to upgrade and expand its San Diego biomanufacturing operations

San Diego CA, USA, 26 April 2017 – Abzena intends to invest $12 million at its San Diego facilities in order to upgrade and expand its biomanufacturing capabilities and capacity to meet increasing customer demand for its services. This investment was made possible following the Company’s recent $32 million financing via a share placing on […] Read more

Abzena to pursue $5 million investment program in Bristol

Bristol PA, USA, 26 April 2017 – Abzena intends to invest $5 million at its Bristol PA facility in order to increase its chemistry research and manufacturing services business for the biopharmaceutical industry. This investment was made possible following the Company’s recent $32 million financing via a share placing on the London Stock Exchange. Abzena […] Read more

Result of General Meeting

Cambridge, UK, 21 April 2017 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’) the life sciences group providing services and technologies to enable the development and manufacture of better biopharmaceutical products, announced on 5 April 2017 a conditional placing to raise approximately £25 million (the “Placing Announcement”).  The Placing was subject to inter alia […] Read more

A short history of monoclonal antibody research in Cambridge

Abzena’s CEO John Burt features in this short film by Cambridge TV. It leads us through a short history of monoclonal antibody research in the Cambridge life science cluster and asks what the next big thing will be in this area of exciting medical technology. John talks on the benefits of  antibody drug conjugates and […] Read more

Result of Bookbuild

NOT FOR RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF IRELAND, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE UNLAWFUL. Abzena plc RESULT OF BOOKBUILD Cambridge, UK, 5 April 2017 – Abzena plc (“Abzena” or the […] Read more

Proposed placing of £25m

NOT FOR RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF IRELAND, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE UNLAWFUL. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR IMMEDIATE RELEASE. Abzena plc PROPOSED PLACING OF £25 MILLION Proceeds […] Read more

‘Abzena inside’ product for neurodegenerative conditions moves into Phase II trial

Cambridge, UK, 6 March 2017 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, notes that one of the ‘Abzena inside’ Composite Human Antibody™ products previously disclosed as being in Phase I trials is moving forwards into a Phase […] Read more

Interested in our services? Get In Touch